Unlock instant, AI-driven research and patent intelligence for your innovation.

Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof

A compound and halogen technology, applied to the active ingredients of heterocyclic compounds, metabolic diseases, organic chemistry, etc., can solve problems such as obvious side effects and weight gain

Inactive Publication Date: 2013-12-25
ZHEJIANG PHARMA COLLEGE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PPARγ is considered to be the main molecular target of glitazone insulin sensitizers. Although glitazones are effective drugs for the treatment of type II diabetes, the side effects of these compounds are very obvious, such as severe liver toxicity, weight gain and anemia, which is mainly due to the fact that glitazones are the main or complete agonists of PPARγ (N · Ajie, D · Rocher, S · Yvonne, CN101098865A)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof
  • Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof
  • Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024]

[0025] 2.61g (10mmol) compound A-1 and 1.24g (10mmol) compound B-1 are dissolved in 10mL DMF, add 4.15g (30mmol) K 2 CO 3 , and then stirred overnight at 120 °C under nitrogen protection. The reaction mixture was cooled slightly and poured into 100 mL of ice water, stirred, adjusted to pH=3-4 with concentrated hydrochloric acid, extracted with 50 mL×3 dichloromethane, combined the extract phases, washed once with brine, dried over anhydrous sodium sulfate, and evaporated on a rotary evaporator. The solvent was evaporated to obtain a residue, and then purified by column chromatography to obtain the pure product of C-1, ESI-MS, m / z=318 ([M+NH 4 ] + ).

[0026] Dissolve 2.43g (8mmol) of compound C-1 in 10mL of dry toluene, stir slowly under cooling in an ice-water bath, and slowly add 2.71g (10mmol) of PBr dropwise 3 Dissolve in 2 mL of dry dichloromethane solution. After the dropwise addition, the reaction mixture was stirred at room temperature for half an hour,...

Embodiment 2-8

[0029] According to the method of Example 1, the compounds of general formula I shown in the table below were prepared.

[0030]

[0031]

Embodiment 9

[0033] The sample was prepared into a suspension of 5 mg / mL concentration with 1% sodium carboxymethyl cellulose, and the administration volume was 0.4 mL / 20 g body weight, which was equivalent to a dose of 100 mg / kg.

[0034] Healthy ICR mice, half male and half male, weighing 20-24g, meet the first-class standard. Animals were fasted for 16 hours, administered intragastrically with the compound to be tested for 15 minutes, and then intraperitoneally injected with 2 g / kg of glucose saline solution. At 0.5h, 1h, 15.h and 2h after modeling, the capillary was regularly taken from the retrobulbar venous plexus of the mouse. Blood was collected, the serum was separated by centrifugation, and the serum glucose content at each time point was determined by the glucose oxidase method. The blank mice were given neither glucose nor the test compound, and the model mice were only given glucose without the test compound.

[0035]

[0036] It can be seen from the data in the above tabl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of diabetes related medicines. The invention particularly relates to tetrazole-carboxylic-acid-containing compounds (disclosed as general formula I) capable of treating diabetes as a peroxisome proliferator-activated receptor (PPAR) agonist, and a preparation method and application thereof in treating diabetes. In the general formula I, the groups are defined in the specification.

Description

technical field [0001] The invention relates to the field of medicine related to diabetes. Specifically, the present invention relates to a class of peroxisome proliferator-activated receptor (PPAR) agonists containing a tetrazolium carboxylic acid skeleton that has a therapeutic effect on diabetes, its preparation method and pharmaceutical compositions containing them . Background technique [0002] Diabetes mellitus is a disease in which the patient's ability to control blood sugar is impaired, and the patient has lost, to varying degrees, the ability to respond appropriately to the action of insulin. Most of diabetes is type II diabetes (ie non-insulin-dependent diabetes), accounting for about 80%-90%. Research Kang found that insulin resistance in peripheral tissues (including skeletal muscle, liver and adipose tissue, etc.) It plays a very important role in the occurrence and development. A class of drugs that sensitize patients to their own insulin, insulin sensitiz...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D257/04A61K31/41A61P3/10A61P9/00A61P3/04
Inventor 郭章华
Owner ZHEJIANG PHARMA COLLEGE